Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05519514
Other study ID # BUDE1001
Secondary ID 173-20
Status Completed
Phase Phase 1
First received
Last updated
Start date July 12, 2021
Est. completion date November 15, 2021

Study information

Verified date August 2022
Source Abbott
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, open label, single dose, balanced, two treatment, two sequence, four period, fully replicate, cross over bioequivalence study under fasting condition.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date November 15, 2021
Est. primary completion date August 8, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Normal healthy human adult male and non- pregnant female volunteers between 18-45 years (both ages inclusive) of age. 2. Who is given written informed consent and are willing to participate in the study. 3. Body Mass Index of 18.50 to 30.00 Kg/m2 (both inclusive). 4. No evidence of underlying disease during the pre-study screening, medical history, physical examination and laboratory investigations performed within 21 days prior to commencement of the study. 5. Pre-study screening laboratory tests are either normal or within acceptable limits or are considered by the Investigator to be of no clinical significance with respect to participation in the study. 6. Negative test results for alcohol (in breath or in urine) and urine drugs of abuse. 7. Who is negative or non-reactive for antibodies to HIV 1 and 2, hepatitis B & C and Rapid Plasma Reagin. 8. 12 lead ECG recording within normal or within acceptable limits or as considered by the Investigator to be of no clinical significance with respect to his/ her participation in the study. 9. Normal or not clinically significant chest X-ray (PA) taken within 06 months before the day of dosing. 10. Who will be available for the entire study period and is capable of understanding and communicating with the investigators and clinical study facility staff. 11. Female volunteers who are having negative results in urine pregnancy test during screening and negative Beta hCG-test at the time of check-in. 12. Females with child-bearing potential must agree to use an acceptable method of contraception at least 2 days prior to dosing of IP, during the study & for 03 days following their last dose of IP. 13. Male subjects and/or Female subject's partner must agree to use condoms, vasectomy or spermicide in addition to female contraception for additional protection against conception throughout the study. Exclusion Criteria: 1. Known history of hypersensitivity/ allergic to Budesonide or any component of the formulation and/or to any other related drug. 2. History or presence of significant cardiovascular, respiratory, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease and malignancy. 3. Female volunteers who are: - Nursing mothers. - Positive result in beta hCG test. - Lactating women (currently breast feeding). - Female subjects not confirming to using birth control measures, from the date of screening until the completion of the study. Abstinence, barrier methods (condom, diaphragm, etc.) are acceptable. - Using hormonal contraceptives either oral or implants. 4. History/presence of significant alcohol dependence (abuse) or drug abuse within the past 1year, current alcohol abuse (> 5 units/week, 1 unit= 10 mL or 8 g of pure alcohol) or suspected abuse. 5. Everyday smoker (who has smoked at least 100 cigarettes in her lifetime, and who now smokes every day) or consumption of tobacco products. 6. History/presence of Asthma. 7. History/presence of urticaria or other allergic type reactions after taking any medication. 8. History/presence of Clinically significant illness within 04 weeks before the start of the study. 9. History/presence of significant Hypersensitivity to heparin. 10. History of clinically relevant allergy (except for untreated, asymptomatic, seasonal allergies at time of dosing) or any allergic reactions to any drugs. 11. Who is scheduled for surgery any time during study or within 03 days after study completion. 12. History of difficulty in donating blood. 13. Who has unsuitable veins for repeated vein puncture. Who is participating in any other clinical or bioequivalence study or otherwise would have donated in excess of 350 mL of blood in the last 90 days. 15. Who has taken prescription medication or OTC products (including vitamins and natural products) within 14 days prior to dosing of IP in Period 1, including topical medication. 16. Who was hospitalized within 28 days prior to administration of the study medication. 17. History of difficulty in swallowing. 18. Evidence of skin lesions on forearm of signs of vein puncture on the forearm suggestive of recent donation or participation in clinical trial. 19. Who has Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the Investigator. 20. Who has Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the Investigator. 21. Who is tested positive for COVID-19 test.

Study Design


Intervention

Drug:
Cortiment
Budesonide 9 mg prolonged release tablets
Budesonide
Experimental (Budesonide 9 mg prolonged release tablets)

Locations

Country Name City State
India Study Site Mangalore

Sponsors (1)

Lead Sponsor Collaborator
Abbott

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bioequivalence of Test Product (T) Vs Reference Product (R) Pharmacokinetic parameters: Cmax (Maximum plasma concentration) Cmax (Maximum plasma concentration) Till 72 hours post dose after each dosing
Primary Bioequivalence of Test Product (T) Vs Reference Product (R) Pharmacokinetic Parameters: AUC0-t (area under the curve) AUC0-t (area under the curve) Till 72 hours post dose after each dosing
Secondary Safety and tolerability of Test Product (T) and the Reference Product (R) Serious adverse events Incidences of Serious Adverse events Till 30 days since last dosing period
Secondary Safety and tolerability of Test Product (T) and the Reference Product (R) Systolic and diastolic blood pressure Vital Signs assessment in terms of:
Systolic and diastolic blood pressure measured as mm of Hg.
Till 72 hours post dose after each dosing
Secondary Safety and tolerability of Test Product (T) and the Reference Product (R) Pulse rate Vital Signs assessment in terms of:
Pulse rate measured as bpm.
Till 72 hours post dose after each dosing
Secondary Safety and tolerability of Test Product (T) and the Reference Product (R) Oral temperature Vital Signs assessment in terms of:
Oral temperature measured as degree fahrenheit (°F).
Till 72 hours post dose after each dosing
Secondary Safety and tolerability of Test Product (T) and the Reference Product (R) Wellbeing assessment: Wellbeing assessment by questioning the subjects about their health status. Wellbeing assessment will be done as per the study site's applicable standard operating procedure, initially subjects wellbeing is recorded in "wellbeing form" by asking general questions like "How do you feel?", how are you feeling since last asked?.
Further, overall subject response is then transcribed into the subject study CRF as below:
Is overall wellbeing of the Volunteer Satisfactory? Satisfactory / Not satisfactory
If it is not satisfactory, the same is treated as AE and is recorded in applicable AE form as per process.
Till 72 hours post dose after each dosing
Secondary Safety and tolerability of Test Product (T) and the Reference Product (R) adverse events Incidences of adverse events Till 21 days from AE occurence
Secondary Safety and tolerability of Test Product (T) and the Reference Product (R) abnormal laboratory values No of subjects with abnormal laboratory values. Lab values for hematology, biochemistry and urine analysis Till 21 days from AE occurence
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1